Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 2/2017

Open Access 01-02-2017 | Case Based Review

Sulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis

Authors: Nehal Narayan, Shirley Rigby, Francesco Carlucci

Published in: Clinical Rheumatology | Issue 2/2017

Login to get access

Abstract

Sulfasalazine has long been used for the treatment of rheumatoid arthritis and is often chosen as a first-line treatment. Here, we report a case of sulfasalazine-induced autoimmune thrombocytopenia and review the mechanisms behind drug-induced immune thrombocytopenia (DITP) and the approach to its diagnosis and management.
Literature
1.
Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B (1997) Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Rheumatology 36:1089–1094CrossRef
2.
Cantarini L, Tinazzi I, Biasis D, Fioravanti A, Galeazzi M (2007) Sulfasalazine-induced immune thrombocytopenia. Postgraduate. Med J 83:e1
3.
Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B (2000) The bleeding risk and natural history of idiopathicthrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 160:1630–1638CrossRefPubMed
4.
5.
6.
Aster RH, Curtis BR, McFarland JG, Bougie DW (2009) Drug-induced immune thrombocytopenia: pathogenesis, diagnosis and management. J Thromb Haemost 7:911–918CrossRefPubMedPubMedCentral
7.
Curtis BR (2014) Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing and pathogenic mechanisms. Immunohematology 30:55–65PubMed
8.
George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, Vondracek T (1998) Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 129:886–890CrossRefPubMed
9.
British Committee for Standards in Haematology, Blood Transfusion Task Force (2003) Guidelines for the use of platelet transfusions. Br J Haematol 122:10–23CrossRef
Metadata
Title
Sulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis
Authors
Nehal Narayan
Shirley Rigby
Francesco Carlucci
Publication date
01-02-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 2/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3420-9

Other articles of this Issue 2/2017

Clinical Rheumatology 2/2017 Go to the issue

Brief Report

Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis

Original Article

National survey of pediatric hospitalizations due to Kawasaki disease and coronary artery aneurysms in the USA

Original Article

Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus

Brief Report

Impact of the size and number of swollen joints on serum C-reactive protein level and erythrocyte sedimentation rate in rheumatoid arthritis: a cross-sectional study in Japan

Original Article

Juvenile dermatomyositis: a tertiary center experience

Brief Report

Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits